Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Exploratory Study to Assess the Safety, Tolerability, Colonic Tissue Exposure, and Anti-Inflammatory Effects of Two Different Doses of SRT2104 in Subjects With Mild to Moderate Ulcerative Colitis

NCT01453491 is registered in ClinicalTrials.gov with Sirtris, a GSK Company as lead sponsor.

NCT NCT01453491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01453491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Exploratory Study to Assess the Safety, Tolerability, Colonic Tissue Exposure, and Anti-Inflammatory Effects of Two Different Doses of SRT2104 in Subjects With Mild to Moderate Ulcerative Colitis
Lead sponsor
Sirtris, a GSK Company
Phase
Phase 1
Overall status
Completed
Start date
February 13, 2012
Completion date
March 18, 2013
Enrollment
17 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

colitis, ulcerative